Showing 1 - 2 results of 2 for search 'D. Pollyea', query time: 0.02s Refine Results
  1. 1
    P584: OVERALL SURVIVAL WITH INTENSIVE CHEMOTHERAPY (IC) VS NON-IC IN PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AML FROM THE CONNECT® MYELOID DISEASE REGISTRY INELIGIBLE FOR RANDOMIZED CLINICAL TRIALS (RCT)

    P584: OVERALL SURVIVAL WITH INTENSIVE CHEMOTHERAPY (IC) VS NON-IC IN PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AML FROM THE CONNECT® MYELOID DISEASE REGISTRY INELIGIBLE FOR RANDOMIZ... by H. Erba, D. Pollyea, M. Sekeres, G. Garcia-Manero, K. Seiter, I. DeGutis, P. Kiselev, A. McBride, E. Yu, G. Roboz

    Published 2022-06-01
    Get full text
    Article
  2. 2
    P492: TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED ADULT PATIENTS SELECTED FOR RARA-POSITIVE AML WHO ARE INELIGIBLE FOR STANDARD INDUCTION THERAPY (SELECT AML-1)

    P492: TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED ADULT PATIENTS SELECTED FOR RARA-POSITIVE AML WHO ARE INELIGIBLE FOR STANDARD INDUCTION TH... by E. Stein, S. de Botton, A. Pigneux, C. McMahon, B. Ball, G. Borthakur, A. Eghtedar, S. Kambhampati, J. Tache, E. Wang, H. Kelley, A. Volkert, K. Baker, Q. Kang-Fortner, G. Hodgson, C. Madigan, E. Warlick, D. Roth, M. Kelly, D. Pollyea

    Published 2022-06-01
    Get full text
    Article

Search Tools: